Skip to main content
Premium Trial:

Request an Annual Quote

Fisher to Acquire Cellomics for $49M; Q2 Revs Jump 33 Percent, Profit Doubles

NEW YORK, Aug. 4 (GenomeWeb News) - Fisher Scientific will acquire cellular imaging company Cellomics for $49 million in cash, and testing lab Lancaster Laboratories for $150 million in cash, the company said yesterday. Fisher also reported increased revenues and earnings for the second quarter of 2005.

 

Fisher said that it will closely collaborate with Carl Zeiss Jena, Cellomics' largest shareholder, in the high-content screening field. Cellomics had $13 million in revenues in 2004.

 

Fisher's revenues for the quarter increased 33 percent to $1.4 billion from $1 billion during the year-ago quarter. Excluding currency effects, organic revenues grew by 5.2 percent. Sales of scientific products and services accounted for 74 percent of total revenues this quarter.

 

The company did not break out its research and development expenses for the quarter.

 

The company had a net income this quarter of $101.4 million, or $.80 per share, more than double last year's $44.7 million, or $.64 per share, during the same period. This quarter's income included $16 million associated with discontinued operations, among them the sale of Atos Medical.

 

As of June 30, Fisher Scientific had $155.2 million in cash and cash equivalents.

 

Fisher also said it completed its acquisition of McKesson BioServices, a company managing biological specimens and clinical trial material, for $60 million on July 31.

The Scan

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk off venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.